Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study |
| |
Authors: | Hong Kyoung Sup Kim You Sun Han Dong Soo Choi Chang Hwan Jang Byung-Ik Park Young-Sook Lee Kang-Moon Lee Soo Teik Kim Hyun-Soo Kim Joo Sung |
| |
Institution: | Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. |
| |
Abstract: | Background/AimsCiprofloxacin has been widely prescribed for acute infectious diarrhea. However, the resistance to this drug is increasing. Rifaximin is a novel but poorly absorbed rifamycin derivative. This study evaluated and compared the efficacies of rifaximin and ciprofloxacin for the treatment of acute infectious diarrhea.MethodsWe performed a randomized controlled multicenter study in Korea. Patients with acute diarrhea were enrolled and randomized to receive rifaximin or ciprofloxacin for 3 days. The primary efficacy endpoint was the time to last unformed stool (TLUS). Secondary endpoints were enteric wellness (reduction of at least 50% in the number of unformed stools during 24-hour postenrollment intervals), general wellness (subjective feeling of improvement), and proportion of patients with treatment failure.ResultsIntent-to-treat analysis (n=143) showed no significant difference between the rifaximin and ciprofloxacin groups in the mean TLUS (36.1 hours vs 43.6 hours, p=0.163), enteric wellness (49% vs 57%, p=0.428), general wellness (67% vs 78%, p=0.189), or treatment failure rate (9% vs 12%, p=0.841). The adverse events did not differ significantly between the two groups.ConclusionsThese results suggest that rifaximin is as safe and effective as ciprofloxacin in the treatment of acute infectious diarrhea. |
| |
Keywords: | Acute infectious diarrhea Rifaximin Ciprofloxacin |
本文献已被 PubMed 等数据库收录! |
|